# US 2024/0366652 A1 · Osteoarthritis progression inhibitor and progression inhibition kit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0366652 A1
- Document ID: US20240366652A1
- Status: Published application
- Kind: A1
- Application number: 18/689,008
- Filed: 2022-09-02
- Published: 2024-11-07
- Earliest claimed: 2021-09-06
- Assignees: Kyushu University, National University Corporation
- Applicants: Kyushu University, National University Corporation
- Inventors: Yasuharu NAKASHIMA; Yukio AKASAKI; Takuya SUEISHI; Masakazu TOYA; Masanari KUWAHARA; Taisuke UCHIDA; Tomoaki TSUTSUI; Hidetoshi TSUSHIMA
- Web page: https://patentgrep.com/patent/US20240366652A1

## CPC

- A61K 31/728: Hyaluronic acid
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12Y 207/11016: G-Protein-coupled receptor kinase (2.7.11.16)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

An osteoarthritis progression inhibitor contains, as active substances, a G protein-coupled receptor kinase 5 inhibitor, and hyaluronic acid or a pharmaceutically acceptable salt thereof. The G protein-coupled receptor kinase 5 inhibitor may be Amlexanox. The osteoarthritis progression inhibitor may be administered by intraarticular injection. An osteoarthritis progression inhibition kit contains a G protein-coupled receptor kinase 5 inhibitor, and hyaluronic acid or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

An osteoarthritis progression inhibitor, comprising, as active substances:
a G protein-coupled receptor kinase 5 inhibitor; and
hyaluronic acid or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The osteoarthritis progression inhibitor according to claim 1, wherein the G protein-coupled receptor kinase 5 inhibitor is Amlexanox.

### Claim 3 (depends on 1)

The osteoarthritis progression inhibitor according to claim 1, wherein the osteoarthritis progression inhibitor is administered by intraarticular injection.

### Claim 4

An osteoarthritis progression inhibition kit, comprising:
a G protein-coupled receptor kinase 5 inhibitor; and
hyaluronic acid or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2)

The osteoarthritis progression inhibitor according to claim 2, wherein the osteoarthritis progression inhibitor is administered by intraarticular injection.

### Claim 6

A method of preventing, treating, or inhibiting the progression of osteoarthritis, comprising administering effective doses of a G protein-coupled receptor kinase 5 inhibitor and hyaluronic acid or a pharmaceutically acceptable salt thereof to a human patient or an animal patient in need thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the G protein-coupled receptor kinase 5 inhibitor is Amlexanox.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the G protein-coupled receptor kinase 5 inhibitor and hyaluronic acid or a pharmaceutically acceptable salt thereof are administered by intraarticular injection.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the Amlexanox and hyaluronic acid or a pharmaceutically acceptable salt thereof are administered by intraarticular injection.
